Daclatasvir + asunaprevir + beclabuvir ± ribavirin for chronic <scp>HCV</scp> genotype 1‐infected treatment‐naive patients
Gregory T. Everson(ColdQuanta, Inc., DBA Infleqtion (United States)), David Gardiner(Bristol-Myers Squibb (Germany)), Norman Gitlin(NYU Langone Health), Karen Sims(Bristol-Myers Squibb (Germany)), Lynn R. Webster(Adherent Technologies (United States)), Federico Hinestrosa(University of Central Florida), Tarek Hassanein, Trevor Hawkins(University of Florida), M. Rodríguez‐Torres(Puerto Rico Community Foundation), Paul J. Thuluvath(University of Maryland, Baltimore), Vinod K. Rustgi, Tadesse Desta(Precision Research Institute), Eric Lawitz(The University of Texas at San Antonio Health Science Center), Zobair M. Younossi(Georgetown University), Fiona McPhee(Bristol-Myers Squibb (United States)), Dennis M. Grasela(Bristol-Myers Squibb (United States)), James Levin(Cidara Therapeutics (United States)), Timothy Eley(Bristol-Myers Squibb (United States)), Howard Schwartz(Clinical Research Associates), Shu‐Pang Huang(Bristol-Myers Squibb (United States))
Cited by 26
Related Papers
A multisociety Delphi consensus statement on new fatty liver disease nomenclature
|Hepatology|2023|2.9k
A multisociety Delphi consensus statement on new fatty liver disease nomenclature
|Journal of Hepatology|2023|2.7k
Sofosbuvir for Previously Untreated Chronic Hepatitis C Infection
|New England Journal of Medicine|2013|1.8k
Obeticholic acid for the treatment of non-alcoholic steatohepatitis: interim analysis from a multicentre, randomised, placebo-controlled phase 3 trial
|The Lancet|2019|1.2k
Ledipasvir and Sofosbuvir for 8 or 12 Weeks for Chronic HCV without Cirrhosis
|New England Journal of Medicine|2014|1.1k